Skip to main content

Table 4 Comparison between the intravenous non-high-dose and high-dose PPI after case-controlled matching for the subgroup of low risk patients (Rockall score < 6)

From: Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis

Characteristics Non-high-dose Group (n = 27) High-dose Group (n = 27) p-value
Age (years) 65.8 ± 3.8 62.4 ± 14.7 0.991
Female gender, n (%) 4(14.8) 10(37.0) 0.119
Creatinine(mg/dl) 1.3 ± 0.5 1.5 ± 1.5 0.100
Hb (g/L) 95.4 ± 25.1 106.0 ± 29.9 0.340
Platelets (× 109/L) 202.2 ± 81.1 246.5 ± 91.6 0.151
Use of NSAIDs, n (%) 3(11.1) 5(18.5) 0.704
Use of aspirin, n (%) 2(7.4) 1(3.7) 1.000
Use of clopidogrel, n (%) 1(3.7) 2(7.4) 1.000
Use of wafarin, n (%) 1(3.7) 3(11.1) 0.610
Shock at presentation 9(33.3) 11(40.7) 0.573
Coexisting illness, n (%)    
CKD III, IV and V 7(25.9)/0 7(25.9)/0 1.000
COPD 1(3.7) 0 1.000
CAD 2(7.4) 2(7.4) 1.000
DM 7(25.9) 8(29.6) 0.761
CVA 3(11.1) 5(18.5) 0.704
Liver Cirrhosis 1(3.7) 1(3.7) 1.000
Rockall score 4.5 ± 0.6 4.5 ± 0.6 1.000
Time to endoscopy (hours) 10.4 ± 11.3 10.6 ± 9.9 0.904
PRBC BT(mL) 907.4 ± 1109.7 1064.8 ± 1003.8 0.863
Ulcer size (cm) 1.1 ± 0.7 0.9 ± 0.6 0.506
Multiple ulcers, n (%) 7(25.9) 9(33.3) 0.182
Forrest classification Ia/Ib/IIa/IIb 0/18/2/7 0/18/2/7 1.000
Re-bleeding, n (%) 3(11.1) 3 (11.1) 1.000
Surgery, n (%) 0 0 1.000
Hospital stay (days) 5.7 ± 5.6 11.7 ± 8.6 0.031*
Mortality, n (%), bleeding related and other causes 0/0 0/1 (3.7) 1.000
  1. Abbreviation: Hb, hemoglobin; NSAID, nonsteriodal anti-inflammatory drug; CKD, chronic kidney disease; PPI, proton-pump inhibitor; DM, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CVA, cerebrovascular accident; BT, blood transfusion. * p < 0.05